CL2007002068A1 - Uso de dabigatran, etexilato de dabigatran, (n-2-piridil-n-2-etoxicarboniletil)amida del acido 1-metil-2-[4-(n-hidroxiamidino)fenilaminoetil]bencimidazol-5-il-carboxilico, melagatran, ximelagatran, hirudina, hirulog y argatroban para el tratamiento de infarto cerebral, infarto de miocardio, trombosis, embolia pulmonar, entre otras. - Google Patents
Uso de dabigatran, etexilato de dabigatran, (n-2-piridil-n-2-etoxicarboniletil)amida del acido 1-metil-2-[4-(n-hidroxiamidino)fenilaminoetil]bencimidazol-5-il-carboxilico, melagatran, ximelagatran, hirudina, hirulog y argatroban para el tratamiento de infarto cerebral, infarto de miocardio, trombosis, embolia pulmonar, entre otras.Info
- Publication number
- CL2007002068A1 CL2007002068A1 CL2007002068A CL2007002068A CL2007002068A1 CL 2007002068 A1 CL2007002068 A1 CL 2007002068A1 CL 2007002068 A CL2007002068 A CL 2007002068A CL 2007002068 A CL2007002068 A CL 2007002068A CL 2007002068 A1 CL2007002068 A1 CL 2007002068A1
- Authority
- CL
- Chile
- Prior art keywords
- dabigatran
- treatment
- hydroxyamidino
- phenylaminoethyl
- hirulog
- Prior art date
Links
- 206010008118 cerebral infarction Diseases 0.000 title abstract 2
- 208000026106 cerebrovascular disease Diseases 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 229960003850 dabigatran Drugs 0.000 title 2
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 title 2
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 title 1
- 108010007267 Hirudins Proteins 0.000 title 1
- 102000007625 Hirudins Human genes 0.000 title 1
- 208000010378 Pulmonary Embolism Diseases 0.000 title 1
- 208000007536 Thrombosis Diseases 0.000 title 1
- 150000001408 amides Chemical class 0.000 title 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 title 1
- 229960003856 argatroban Drugs 0.000 title 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 title 1
- 108010055460 bivalirudin Proteins 0.000 title 1
- 229960001500 bivalirudin Drugs 0.000 title 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 title 1
- 229940006607 hirudin Drugs 0.000 title 1
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 title 1
- 229960002137 melagatran Drugs 0.000 title 1
- 208000010125 myocardial infarction Diseases 0.000 title 1
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 title 1
- 229960001522 ximelagatran Drugs 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 abstract 1
- 208000006193 Pulmonary infarction Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000007575 pulmonary infarction Effects 0.000 abstract 1
- 239000003868 thrombin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Uso de compuestos específicos inhibidores directos de la trombina, para el tratamiento y/o profilaxis de una enfermedad seleccionada de infarto cerebral, trastornos cardiovasculares e infarto pulmonar entre otras.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06117341 | 2006-07-17 | ||
| EP07102512 | 2007-02-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2007002068A1 true CL2007002068A1 (es) | 2008-01-18 |
Family
ID=38819569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2007002068A CL2007002068A1 (es) | 2006-07-17 | 2007-07-13 | Uso de dabigatran, etexilato de dabigatran, (n-2-piridil-n-2-etoxicarboniletil)amida del acido 1-metil-2-[4-(n-hidroxiamidino)fenilaminoetil]bencimidazol-5-il-carboxilico, melagatran, ximelagatran, hirudina, hirulog y argatroban para el tratamiento de infarto cerebral, infarto de miocardio, trombosis, embolia pulmonar, entre otras. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080039391A1 (es) |
| EP (1) | EP2043631A2 (es) |
| JP (1) | JP2009543842A (es) |
| KR (1) | KR20090029849A (es) |
| AR (1) | AR061996A1 (es) |
| AU (1) | AU2007276205A1 (es) |
| BR (1) | BRPI0715492A2 (es) |
| CA (1) | CA2657266A1 (es) |
| CL (1) | CL2007002068A1 (es) |
| EA (1) | EA200900091A1 (es) |
| EC (1) | ECSP099049A (es) |
| IL (1) | IL196526A0 (es) |
| MX (1) | MX2009000602A (es) |
| NO (1) | NO20090010L (es) |
| TW (1) | TW200817001A (es) |
| WO (1) | WO2008009638A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201100358A1 (ru) * | 2008-08-19 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Дабигатран для чрескожной хирургической катетеризации сердца |
| US20110190352A1 (en) * | 2008-08-19 | 2011-08-04 | Boehringer Ingelheim International Gmbh | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| CN103463083A (zh) * | 2008-11-11 | 2013-12-25 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良有效性的方法 |
| CN102209544A (zh) * | 2008-11-11 | 2011-10-05 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良安全性的方法 |
| AU2009315731A1 (en) * | 2008-11-11 | 2010-05-20 | Boehringer Ingelheim International Gmbh | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy |
| HUP1000069A2 (en) * | 2010-02-02 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | New salts for the preparation of pharmaceutical composition |
| JP6155187B2 (ja) | 2010-03-30 | 2017-06-28 | ヴァーセオン コーポレイション | トロンビンの阻害剤としての多置換芳香族化合物 |
| WO2013175494A2 (en) * | 2012-04-10 | 2013-11-28 | Rubicon Research Private Limited | Controlled release pharmaceutical formulations of direct thrombin inhibitors |
| WO2014001220A1 (en) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| EP2722033A1 (en) * | 2012-10-19 | 2014-04-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical Compositions of Dabigatran Free Base |
| EP2722034B1 (en) * | 2012-10-19 | 2020-09-16 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
| WO2014145986A1 (en) | 2013-03-15 | 2014-09-18 | Verseon, Inc. | Multisubstituted aromatic compounds as serine protease inhibitors |
| ES2791749T3 (es) | 2013-03-15 | 2020-11-05 | Verseon Corp | Halogenopirazoles como inhibidores de la trombina |
| KR102205845B1 (ko) | 2013-10-28 | 2021-01-22 | 삼성전자주식회사 | 입자에 기반한 모델링 방법 및 장치 |
| KR20170048410A (ko) | 2014-09-17 | 2017-05-08 | 베르선 코포레이션 | 세린 프로테아제 저해제로서의 피라졸릴-치환된 피리돈 화합물 |
| AU2016224974B2 (en) | 2015-02-27 | 2019-09-26 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| WO2017151042A1 (en) * | 2016-03-02 | 2017-09-08 | Marvel Pharma Consulting | Pharmaceutical compositions for on demand anticoagulant therapy |
| IL280078B2 (en) | 2018-07-13 | 2024-04-01 | Verseon Int Corporation | Thrombin inhibitors, formulations, and uses thereof |
| US12251377B2 (en) | 2019-03-06 | 2025-03-18 | University Of Rochester | Anticoagulant compositions and uses thereof |
| CN113968840B (zh) * | 2020-07-22 | 2025-03-25 | 北京四环制药有限公司 | 一种高纯度达比加群酯及其制备方法和其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| NZ286082A (en) * | 1995-03-15 | 1998-09-24 | Behringwerke Ag | Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6462021B1 (en) * | 2000-11-06 | 2002-10-08 | Astrazeneca Ab | Use of low molecular weight thrombin inhibitor |
| SI1870100T1 (sl) * | 2002-03-07 | 2012-05-31 | Boehringer Ingelheim Int | Metansulfonat etil estra heksiloksikarbonilamino imino metil fenilamino metil metil H benzimidazol karbonil piridin il amino propionske kisline |
| DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
| KR20040076203A (ko) * | 2003-02-24 | 2004-08-31 | 주식회사 엘지생명과학 | 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법 |
| KR20060007034A (ko) * | 2003-04-24 | 2006-01-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 혈전색전증 질환 및 트롬빈의 과형성 및/또는 트롬빈수용체의 상승된 발현에 의해 유발된 질환 및 장애를치료하고 예방하기 위한, 디피리다몰 또는 모피다몰의 용도 |
| US20060198836A1 (en) * | 2003-07-17 | 2006-09-07 | Smithkline Beecham Corporation | Method of treating hit patients with argatroban |
| DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
| DE10341043A1 (de) * | 2003-09-03 | 2005-03-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue oral zu applizierende Darreichungsform für 3-[(2-{[4-Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester und dessen Salze |
| JP2006111563A (ja) * | 2004-10-14 | 2006-04-27 | Japan Health Science Foundation | 動脈硬化抑制剤 |
-
2007
- 2007-07-13 AR ARP070103123A patent/AR061996A1/es unknown
- 2007-07-13 WO PCT/EP2007/057255 patent/WO2008009638A2/en not_active Ceased
- 2007-07-13 CA CA002657266A patent/CA2657266A1/en not_active Abandoned
- 2007-07-13 CL CL2007002068A patent/CL2007002068A1/es unknown
- 2007-07-13 KR KR1020097003161A patent/KR20090029849A/ko not_active Withdrawn
- 2007-07-13 BR BRPI0715492-5A patent/BRPI0715492A2/pt not_active IP Right Cessation
- 2007-07-13 JP JP2009519954A patent/JP2009543842A/ja active Pending
- 2007-07-13 EA EA200900091A patent/EA200900091A1/ru unknown
- 2007-07-13 MX MX2009000602A patent/MX2009000602A/es not_active Application Discontinuation
- 2007-07-13 AU AU2007276205A patent/AU2007276205A1/en not_active Abandoned
- 2007-07-13 EP EP07787523A patent/EP2043631A2/en not_active Withdrawn
- 2007-07-16 TW TW096125875A patent/TW200817001A/zh unknown
- 2007-07-17 US US11/779,029 patent/US20080039391A1/en not_active Abandoned
-
2009
- 2009-01-02 NO NO20090010A patent/NO20090010L/no not_active Application Discontinuation
- 2009-01-09 EC EC2009009049A patent/ECSP099049A/es unknown
- 2009-01-15 IL IL196526A patent/IL196526A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2657266A1 (en) | 2008-01-24 |
| AR061996A1 (es) | 2008-08-10 |
| WO2008009638A3 (en) | 2008-04-24 |
| EA200900091A1 (ru) | 2009-06-30 |
| BRPI0715492A2 (pt) | 2013-03-19 |
| ECSP099049A (es) | 2009-02-27 |
| MX2009000602A (es) | 2009-01-28 |
| US20080039391A1 (en) | 2008-02-14 |
| TW200817001A (en) | 2008-04-16 |
| JP2009543842A (ja) | 2009-12-10 |
| AU2007276205A1 (en) | 2008-01-24 |
| KR20090029849A (ko) | 2009-03-23 |
| EP2043631A2 (en) | 2009-04-08 |
| IL196526A0 (en) | 2009-11-18 |
| WO2008009638A2 (en) | 2008-01-24 |
| NO20090010L (no) | 2009-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061996A1 (es) | Indicaciones para los inhibidores directos de la trombina en el campo cardiovascular | |
| PE20170306A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| DK3911648T3 (da) | 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf | |
| CL2010000395A1 (es) | Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) | |
| CR9755A (es) | Derivados de 1-h-pirrol sustituidos con 1-heterocíclilsulfonilo, 2aminoetilo, 5-(hetero-) arilo como inhibidores de la secreción de ácido | |
| CR20150050A (es) | Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona y composiciones que comprenden y métodos para utilizar las mismas | |
| CU23829B1 (es) | Compuestos y composiciones como inhibidores de las proteínas cinasas | |
| DK3980411T3 (da) | N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamid som en human ctps1-inhibitor til behandling af proliferative sygdomme | |
| EA201691997A1 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| MY197564A (en) | Urat1 inhibitor and use thereof | |
| EA202192426A1 (ru) | Ингибиторы путей jak1 для лечения хронической дисфункции аллотрансплантата легких | |
| AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
| ECSP15004585A (es) | Procesos para la preparación de (s)-3-4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y formas farmacéuticamente aceptables de la misma | |
| AR062057A1 (es) | Uso de los inhibidores directos de la trombina | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| CL2007002067A1 (es) | Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras. | |
| CL2019000377A1 (es) | Compuesto para uso en el tratamiento de hipotensión ortostática neurogénica. | |
| FR2974729B1 (fr) | Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent | |
| PE20070806A1 (es) | Composicion farmaceutica que comprende un derivado de diarilurea | |
| CO2017008426A2 (es) | Ácido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4- [(5-metiloxazol-2-carbonil)amino]pentanoico | |
| UY29964A1 (es) | Formas de cristal f,g,h,i, y k del mesilato de imatinib | |
| DK1856063T3 (da) | 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme | |
| HRP20080544T3 (hr) | Formulacije benzotiazola i njihova uporaba | |
| DK1912954T3 (da) | Hidtil ukendte cysteinproteaseinhibitorer og deres terapeutiske applikationer | |
| MX2024002113A (es) | Un procedimiento para la preparacion de compuesto de triaminopirimidina e intermediarios del mismo. |